Search results
Results From The WOW.Com Content Network
PDE5 inhibitors, such as sildenafil and tadalafil, are used off-label to treat severe ischemia and ulcers in fingers and toes for people with secondary Raynaud's phenomenon; as of 2016, their role more generally in Raynaud's was not clear.
Viagra inhibits PDE5 and acts as a vasodilator (something that dilates blood vessels and increases blood flow). ... Raynaud’s phenomenon is usually more annoying than serious — although severe ...
Sildenafil has been shown to be at least as effective as calcium channel blockers in treating severe Raynaud's phenomenon (RP) associated with systemic sclerosis and digital ulceration. [3] When given sildenafil for 4 weeks subjects had reduced mean frequency and duration of Raynaud attacks and a significantly lowered mean Raynaud's condition ...
PDE5 inhibitors have been used as a second line therapy in severe cases of Raynaud phenomenon when it is related to systemic sclerosis per The European Society for Vascular Medicine guidelines. [3] Sildenafil, the prototypical PDE5 inhibitor, was originally discovered during the search of a novel treatment for angina.
In people with Raynaud’s phenomenon, cold temperatures or stress trigger spasms in the small blood vessels near the surface of the skin, causing the vessels to constrict and limit blood flow.
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction. [1] It is an α 1-adrenergic antagonist. [2] In the United Kingdom, Moxisylte is marketed as Opilon (Archimedes Pharma UK Ltd) and is used for the short-term treatment of primary Raynaud's syndrome.
Raynaud's Disease Auguste Gabriel Maurice Raynaud (10 August 1834 – 29 June 1881) was the French medical doctor who discovered Raynaud syndrome , a vasospastic disorder which contracts blood vessels in extremities and is the "R" in the CREST syndrome acronym, in the late 19th century.
as a vasodilator in severe Raynaud's phenomenon or ischemia of a limb; in pulmonary hypertension. in primary pulmonary hypertension (PPH) The production of prostacyclin is inhibited by the action of NSAIDs on cyclooxygenase enzymes COX1 and COX2. These convert arachidonic acid to prostaglandin H2 (PGH 2), the immediate precursor of prostacyclin.